PubRank

A Küpfer

Author PubWeight™ 43.43‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984 2.66
2 Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985 2.50
3 Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000 2.24
4 False positives with current carbocisteine protocol for sulphoxidation phenotyping. Lancet 1990 2.05
5 Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther 1976 1.35
6 Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1984 1.26
7 Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther 1984 1.25
8 Inherited defects of hepatic drug metabolism. Semin Liver Dis 1983 1.17
9 Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther 1987 1.03
10 Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther 1981 1.00
11 Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 1986 1.00
12 [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population]. Schweiz Med Wochenschr 1982 0.99
13 Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos 1996 0.97
14 Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man. J Pharmacol Exp Ther 1982 0.94
15 Ifosfamide by continuous infusion to prevent encephalopathy. Lancet 1990 0.94
16 Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther 1985 0.93
17 Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation. J Neurol 1986 0.90
18 Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab Dispos 1998 0.87
19 Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1999 0.83
20 Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol 1999 0.83
21 Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Dispos 1998 0.83
22 Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol 1991 0.82
23 Polymorphic acetylation and aminopyrine demethylation in Gilbert's syndrome. Eur J Clin Invest 1978 0.82
24 The differential localization of various drug metabolizing systems within the rat liver lobule as determined by the hepatotoxins allyl alcohol, carbon tetrachloride and bromobenzene. J Pharmacol Exp Ther 1981 0.82
25 Analysis of hydroxylated and demethylated metabolites of mephenytoin in man and laboratory animals using gas-liquid chromatography and high-performance liquid chromatography. J Chromatogr 1982 0.82
26 Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans. J Pharmacol Exp Ther 1984 0.81
27 The enigma of ifosfamide encephalopathy. Ann Oncol 1992 0.81
28 A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin. Drug Metab Dispos 1980 0.81
29 Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986 0.81
30 Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol 1991 0.80
31 Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients. Ann Oncol 1990 0.79
32 Induction of drug-metabolizing enzymes by the enantiomers of normephenytoin in the rat. Drug Metab Dispos 1981 0.79
33 [Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration]. Schweiz Med Wochenschr 1989 0.78
34 Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol 1994 0.78
35 Phenytoin therapy for epileptic children: evaluation of salivary and plasma concentrations and of methods of assessing compliance. Dev Med Child Neurol 1981 0.78
36 Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine. Br J Clin Pharmacol 1988 0.78
37 Defective bile acid transport in an animal model of defective debrisoquine hydroxylation. Biochem Pharmacol 1986 0.77
38 Hepatic metabolism of aminopyrine in patients with chronic renal failure. Clin Sci Mol Med 1978 0.77
39 Methylene blue and fatal encephalopathy from ackee fruit poisoning. Lancet 1999 0.77
40 Stereoselectivity of differential routes of drug metabolism: the fate of the enantiomers of [14C]mephenytoin in the dog. J Pharmacol Exp Ther 1979 0.76
41 Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation. Eur J Clin Pharmacol 1986 0.76
42 Depletion of circulating cyst(e)ine by oral and intravenous mesna. Br J Cancer 1993 0.76
43 Importance of oxidative polymorphism on clinical efficacy and side-effects of imipramine--a retrospective study. Pharmacopsychiatry 1988 0.75
44 Intramolecular rearrangement of ifosfamide in aqueous solutions. Lancet 1990 0.75
45 Differences in hepatic drug accumulation and enzyme induction after chronic amiodarone feeding of two rat strains: role of the hydroxylator phenotype? Br J Pharmacol 1990 0.75
46 Urinary bile acid and bile alcohol excretion does not reflect the genetic polymorphism of debrisoquine hydroxylation. Br J Clin Pharmacol 1984 0.75
47 In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man. Biochem Pharmacol 1988 0.75
48 Stereoselective metabolism, pharmacokinetics and biliary elimination of phenylethylhydantoin (Nirvanol) in the dog. J Pharmacol Exp Ther 1977 0.75
49 [Computer tomography of the mediastinum in primary operable bronchogenic carcinoma]. Helv Chir Acta 1984 0.75
50 Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains. Biochem Pharmacol 1982 0.75
51 Stereoselectivity of the arene epoxide pathway of mephenytoin hydroxylation in man. Epilepsia 1984 0.75
52 Analysis of mephenytoin, 4-hydroxymephenytoin and 4-hydroxyphenytoin enantiomers in human urine by cyclodextrin micellar electrokinetic capillary chromatography: simple determination of a hydroxylation polymorphism in man. Electrophoresis 1994 0.75
53 Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility. J Cancer Res Clin Oncol 1991 0.75
54 Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate. Eur J Clin Pharmacol 1986 0.75
55 [Indication and early results of carotid endarterectomy]. Helv Chir Acta 1983 0.75
56 Identification of the "major" polymorphic carbocysteine metabolite as S-(carboxymethylthio)-L-cysteine. Biochem Pharmacol 1991 0.75
57 Relation of in vivo drug metabolism to stereoselective fetal hydantoin toxicology in mouse: evaluation of mephenytoin and its metabolite, nirvanol. J Pharmacol Exp Ther 1982 0.75
58 Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents. Eur J Clin Pharmacol 1983 0.75
59 Pharmacokinetics of R-enantiomeric normephenytoin during chronic administration in epileptic patients. Epilepsia 1986 0.75
60 Identification of mephenytoin metabolites in the dog. Drug Metab Dispos 1980 0.75